Trials / Recruiting
RecruitingNCT06138028
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Qingdao Central Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab） | TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles. |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2025-10-31
- Completion
- 2026-10-31
- First posted
- 2023-11-18
- Last updated
- 2024-07-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06138028. Inclusion in this directory is not an endorsement.